Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Up – Still a Buy?

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $16.25, but opened at $17.15. Teva Pharmaceutical Industries shares last traded at $16.96, with a volume of 3,659,756 shares.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Finally, StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.57.

Teva Pharmaceutical Industries Trading Up 1.8 %

The company has a quick ratio of 0.61, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a 50 day moving average price of $19.93 and a 200 day moving average price of $18.50. The stock has a market capitalization of $18.74 billion, a PE ratio of -11.41, a P/E/G ratio of 1.39 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently added to or reduced their stakes in the stock. Oarsman Capital Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at $44,000. Smithfield Trust Co increased its position in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at $50,000. Finally, Claro Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $52,000. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.